Wanwisa Dejnirattisai

Wanwisa Dejnirattisai

Auto-generated profile, based on publicly available information

Wanwisa Dejnirattisai

Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2021 in Cell
Verified
Journal Article
Open access
WDWanwisa Dejnirattisai
Wanwisa Dejnirattisai
DZDaming Zhou
Daming Zhou
PSPiyada Supasa
Piyada Supasa
CLChang Liu
Chang Liu
AMAlexander J. Mentzer
Alexander J. Mentzer
GSGavin R. Screaton
Gavin R. Screaton
Terminating the SARS-CoV-2 pandemic relies upon pan-global vaccination. Current vaccines elicit neutralizing antibody responses to the virus spike derived from early isolates. However, new strains have emerged with multiple mutations, including P.1 from Brazil, B.1.351 from South Africa, and B.1.1.7 from the UK (12, 10, and 9 changes in the spike, respectively). All have mutations in the ACE2 binding site, with P.1 and B.1.351 having a virtually identical triplet (E484K, K417N/T, and N501Y), which we show confer similar increased affinity for ACE2. We show that, surprisingly, P.1 is significantly less resistant to naturally acquired or vaccine-induced antibody responses than B.1.351, suggesting that changes outside the receptor-binding domain (RBD) impact neutralization. Monoclonal antibody (mAb) 222 neutralizes all three variants despite interacting with two of the ACE2-binding site mutations. We explain this through structural analysis and use the 222 light chain to largely restore neutralization potency to a major class of public antibodies.

20 May 2022 in Cell
Verified
Journal Article
Open access
RNRungtiwa Nutalai
Rungtiwa Nutalai
DZDaming Zhou
Daming Zhou
ATAekkachai Tuekprakhon
Aekkachai Tuekprakhon
HGHelen M. Ginn
Helen M. Ginn
PSPiyada Supasa
Piyada Supasa
GSGavin R. Screaton
Gavin R. Screaton
Highly transmissible Omicron variants of SARS-CoV-2 currently dominate globally. Here, we compare neutralization of Omicron BA.1, BA.1.1, and BA.2. BA.2 RBD has slightly higher ACE2 affinity than BA.1 and slightly reduced neutralization by vaccine serum, possibly associated with its increased transmissibility. Neutralization differences between sub-lineages for mAbs (including therapeutics) mostly arise from variation in residues bordering the ACE2 binding site; however, more distant mutations S371F (BA.2) and R346K (BA.1.1) markedly reduce neutralization by therapeutic antibody Vir-S309. In-depth structure-and-function analyses of 27 potent RBD-binding mAbs isolated from vaccinated volunteers following breakthrough Omicron-BA.1 infection reveals that they are focused in two main clusters within the RBD, with potent right-shoulder antibodies showing increased prevalence. Selection and somatic maturation have optimized antibody potency in less-mutated epitopes and recovered potency in highly mutated epitopes. All 27 mAbs potently neutralize early pandemic strains, and many show broad reactivity with variants of concern.

8 July 2022 in JCI Insight
Verified
Journal Article
Open access
PDF file
AMAnna McNaughton
Anna McNaughton
RPRobert Stephen Paton
Robert Stephen Paton
MEMatthew Derek Edmans
Matthew Derek Edmans
JYJonathan Youngs
Jonathan Youngs
JWJudith Wellens
Judith Wellens
CTCraig Thompson
Craig Thompson
The role of immune responses to previously seen endemic coronavirus epitopes in severe acute respiratory coronavirus 2 (SARS-CoV-2) infection and disease progression has not yet been determined. Here, we show that a key characteristic of fatal outcomes with coronavirus disease 2019 (COVID-19) is that the immune response to the SARS-CoV-2 spike protein is enriched for antibodies directed against epitopes shared with endemic beta-coronaviruses and has a lower proportion of antibodies targeting the more protective variable regions of the spike. The magnitude of antibody responses to the SARS-CoV-2 full-length spike protein, its domains and subunits, and the SARS-CoV-2 nucleocapsid also correlated strongly with responses to the endemic beta-coronavirus spike proteins in individuals admitted to an intensive care unit (ICU) with fatal COVID-19 outcomes, but not in individuals with nonfatal outcomes. This correlation was found to be due to the antibody response directed at the S2 subunit of the SARS-CoV-2 spike protein, which has the highest degree of conservation between the beta-coronavirus spike proteins. Intriguingly, antibody responses to the less cross-reactive SARS-CoV-2 nucleocapsid were not significantly different in individuals who were admitted to an ICU with fatal and nonfatal outcomes, suggesting an antibody profile in individuals with fatal outcomes consistent with an “original antigenic sin” type response.

8 April 2022 in JCI Insight
Verified
Journal Article
Open access
PDF file
AOAne Ogbe
Ane Ogbe
MPMatthew Pace
Matthew Pace
MBMustapha Bittaye
Mustapha Bittaye
TTTimothy Tipoe
Timothy Tipoe
SASandra Adele
Sandra Adele
JFJohn Frater
John Frater
Duration of protection from SARS-CoV-2 infection in people living with HIV (PWH) following vaccination is unclear. In a substudy of the phase II/III the COV002 trial (NCT04400838), 54 HIV + male participants on antiretroviral therapy (undetectable viral loads, CD4 + T cells > 350 cells/μL) received 2 doses of ChAdOx1 nCoV-19 (AZD1222) 4–6 weeks apart and were followed for 6 months. Responses to vaccination were determined by serology (IgG ELISA and Meso Scale Discovery [MSD]), neutralization, ACE-2 inhibition, IFN-γ ELISpot, activation-induced marker (AIM) assay and T cell proliferation. We show that, 6 months after vaccination, the majority of measurable immune responses were greater than prevaccination baseline but with evidence of a decline in both humoral and cell-mediated immunity. There was, however, no significant difference compared with a cohort of HIV-uninfected individuals vaccinated with the same regimen. Responses to the variants of concern were detectable, although they were lower than WT. Preexisting cross-reactive T cell responses to SARS-CoV-2 spike were associated with greater postvaccine immunity and correlated with prior exposure to beta coronaviruses. These data support the ongoing policy to vaccinate PWH against SARS-CoV-2, and they underpin the need for long-term monitoring of responses after vaccination.

16 June 2020 in Vaccines
Verified
Journal Article
Open access
PDF file
CLCésar López-Camacho
César López-Camacho
GLGiuditta De Lorenzo
Giuditta De Lorenzo
JSJose Slon-Campos
Jose Slon-Campos
SDStuart Dowall
Stuart Dowall
PAPeter Abbink
Peter Abbink
ARArturo Reyes-Sandoval
Arturo Reyes-Sandoval
The flavivirus envelope protein domain III (EDIII) was an effective immunogen against dengue virus (DENV) and other related flaviviruses. Whether this can be applied to the Zika virus (ZIKV) vaccinology remains an open question. Here, we tested the efficacy of ZIKV-EDIII against ZIKV infection, using several vaccine platforms that present the antigen in various ways. We provide data demonstrating that mice vaccinated with a ZIKV-EDIII as DNA or protein-based vaccines failed to raise fully neutralizing antibodies and did not control viremia, following a ZIKV challenge, despite eliciting robust antibody responses. Furthermore, we showed that ZIKV-EDIII encoded in replication-deficient Chimpanzee adenovirus (ChAdOx1-EDIII) elicited anti-ZIKV envelope antibodies in vaccinated mice but also provided limited protection against ZIKV in two physiologically different mouse challenge models. Taken together, our data indicate that contrary to what was shown for other flaviviruses like the dengue virus, which has close similarities with ZIKV-EDIII, this antigen might not be a suitable vaccine candidate for the correct induction of protective immune responses against ZIKV.

18 June 2015 in Nature Immunology
Verified
Journal Article
Open access
WDWanwisa Dejnirattisai
Wanwisa Dejnirattisai
WWWiyada Wongwiwat
Wiyada Wongwiwat
SSSunpetchuda Supasa
Sunpetchuda Supasa
XZXiaokang Zhang
Xiaokang Zhang
XDXinghong Dai
Xinghong Dai
GSGavin R Screaton
Gavin R Screaton